Treatment Choices Based on OncotypeDx in the Breast Oncology Care SettingReportar como inadecuado

Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Cancer EpidemiologyVolume 2012 2012, Article ID 941495, 6 pages

Research Article

Health Outcomes and Behavior Program, Division of Cancer Prevention and Control, Moffitt Cancer Center, 12902 Magnolia Drive, MRC-CANCONT, Tampa, FL 33612, USA

School of Nursing, Duke University, Medical Center, P.O. Box 3322, Durham, NC 27710, USA

Department of Surgery, Feinberg School of Medicine, Northwestern University, 251 East Huron Street Galter 3-150, Chicago, IL 60611, USA

Department of Oncologic Sciences, College of Medicine, University of South Florida, 12901 Bruce B. Downs Boulevard, MDC 44, Tampa, FL 33612, USA

Department of Women-s Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA

Department of Anatomic Pathology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA

Received 29 March 2012; Accepted 17 May 2012

Academic Editor: Suzanne C. O-Neill

Copyright © 2012 Teri L. Malo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction. This study aimed to evaluate whether OncotypeDx test results predict receipt of adjuvant chemotherapy in breast cancer patients who received an OncotypeDx recurrence score RS. Materials and Methods. Pathology records were used to identify breast cancer patients who had OncotypeDx testing between December 2004 and January 2009 𝑛 = 1 1 8 . Patient sociodemographic information, tumor characteristics, RS, and treatment-specific data were collected via chart review. RS was classified as follows: low R S ≤ 1 7 , intermediate RS = 18–30, or high R S ≥ 3 1 . Bivariate analyses were conducted to investigate the relationship between adjuvant chemotherapy receipt and each sociodemographic and clinical characteristic; significant sociodemographic and clinical variables were included in a multivariable logistic regression model. Results. In multivariable analysis controlling for tumor size, histologic grade, and nuclear grade, only RS remained significantly associated with chemotherapy uptake. Relative to low RS, an intermediate adjusted odds ratio AOR, 21.24; 95% confidence interval CI, 3.62–237.52 or high AOR, 15.07; 95% CI, 1.28–288.21 RS was associated with a greater odds of chemotherapy uptake. Discussion. Results indicate that RS was significantly associated with adjuvant chemotherapy uptake, suggesting that OncotypeDx results were used to inform treatment decision making, although it is unclear if and how the information was conveyed to patients.

Autor: Teri L. Malo, Isaac Lipkus, Tobi Wilson, Hyo S. Han, Geza Acs, and Susan T. Vadaparampil



Documentos relacionados